Department of Clinical Therapeutics, Alexandra General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Department of Obstetrics and Gynaecology, Alexandra General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Curr Oncol. 2021 Mar 7;28(2):1143-1152. doi: 10.3390/curroncol28020110.
Treatment of elderly patients with neoplasia is challenging. Age is a known prognostic factor in ovarian cancer but the optimal treatment of elderly patients has not been determined. We undertook a retrospective analysis to determine clinical practice in advanced-stage ovarian cancer patients older than 70 years of age. : Medical records of women with high-grade serous ovarian cancer, stage III and IV were retrospectively analyzed. A total of 735 patients were identified with a median age of 61.5 years. 22.4% among them were older than 70 years of age at diagnosis. First-line Progression-Free Survival (PFS) and Overall Survival (OS) were significantly worse in elderly patients in comparison to the younger ones [mPFS 11.3 months vs. 14.8 months, ( < 0.001) and mOS 30.2 months vs. 45.6 months ( < 0.001)]. However, elderly patients were characterized by worse ECOG-Performance Status and they were more frequently treated with Neoadjuvant Chemotherapy followed by Interval Debulking Surgery, while often they were more frequently denied debulking surgery compared to patients under 70 years of age. Moreover, elderly patients received more frequently monotherapy with platinum as frontline treatment. In contrast, there was no significant difference in the outcome of the debulking surgery in comparison to the younger patients or the frequency that gBRCA test was performed. Age over 70 years did not retain its significance for either Progression-Free Survival or Overall Survival when adjusted for all other reported prognostic factors. Elderly ovarian cancer patients have a worse prognosis. Comprehensive geriatric assessment should be performed for the optimal treatment of these patients.
治疗老年肿瘤患者颇具挑战性。年龄是卵巢癌的已知预后因素,但尚未确定老年患者的最佳治疗方法。我们进行了一项回顾性分析,以确定 70 岁以上晚期卵巢癌患者的临床实践。:回顾性分析了高级别浆液性卵巢癌、III 期和 IV 期女性的病历。共确定了 735 名患者,中位年龄为 61.5 岁。其中 22.4%的患者在诊断时年龄超过 70 岁。与年轻患者相比,老年患者的一线无进展生存期(PFS)和总生存期(OS)明显更差[mPFS 11.3 个月 vs. 14.8 个月,(<0.001)和 mOS 30.2 个月 vs. 45.6 个月(<0.001)]。然而,老年患者的 ECOG 表现状态较差,更常接受新辅助化疗后间隔减瘤手术,而与 70 岁以下患者相比,她们经常更频繁地被拒绝减瘤手术。此外,老年患者更常接受铂类单药作为一线治疗。相比之下,与年轻患者相比,减瘤手术的结果或 gBRCA 检测的频率没有差异。在调整所有其他报告的预后因素后,年龄超过 70 岁与无进展生存期或总生存期均无显著相关性。老年卵巢癌患者预后较差。应对这些患者进行全面的老年评估,以实现最佳治疗。